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By 2015, vaccine shortages still remained one of the major problems around the globe, as described in the annual 
secretariat report of the Global Vaccine Action Plan (GVAP). Despite multiple initiatives to reduce vaccine shortages, 
supply interruptions are unexpected and unavoidable. To mitigate the risk of such interruptions, vaccine stockpiles 
have traditionally been the tool of choice. However, the models used to determine vaccine stockpile levels have only 
considered the use of monovalent vaccines, which provide protection against a single disease. This study aims to 
determine optimal stockpile levels for combination vaccines, which provide protection against multiple diseases. First, 
through discrete event simulation, we explore the effect on antigen shortages while maintaining stockpiles of multiple 
vaccines from multiple suppliers with different reliability conditions. We consider policies that mimic those of a 
decision maker that can either use vaccines with the most or the least reliable supply to set up the safety stockpile. 
Second, we propose a stochastic tractable safety stock model that considers the availability of a pool of monovalent 
and combination vaccines in the stockpile. Finally, we contrast the recommendations from the simulation with those 
from the stochastic safety stock model, and we analyze the effect of having a mix of combination and monovalent 
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In 2010, international health organizations such as the World Health Organization (WHO), the United Nations 
Children’s Fund (UNICEF), the National Institute of Allergy and Infectious Diseases (NIAID), the Bill and Melinda 
Gates Foundation, and other partners collectively launched the ‘Decade of Vaccines’ collaboration program [1]. This 
program includes the Global Vaccine Action Plan (GVAP) for the years 2011 to 2020, which aims to immunize every 
child and woman irrespective of their location or economic condition [1]. One of the six strategic objectives of GVAP 
is that every immunization program conducted in each country should have a sustainable vaccine supply [1]. In 2014, 
during the annual assessment of the GVAP goals, the Strategic Advisory Group of Experts on Immunization (SAGE) 
claimed that the goal of attaining target global immunization coverage rates for multiple vaccines was off track. One 
of the main reasons for this was vaccine stockouts due to global supply interruptions [2]. 
Table 1: Global vaccine stockout details 
  2010 2011 2012 2013 2014 
Countries facing minimum one national-level stockout for at least 
one vaccine 
67 66 57 54 50 
Number of stockout events in a year 153 148 120 111 110 
Average number of stockout events per year per country 2.28 2.24 2.11 2.06 2.2 
Average duration of a stockout event (in days) 45.2 35.3 34 32 52.7 
  Sources: GVAP—Monitoring, Evaluation, and Accountability—Secretariat Annual Report 2015 [2]. 
Table 1, illustrates the number of stockout events that occurred globally between 2010 and 2014. On average 58 
countries faced stockouts every year between 2010 and 2014. In 2014, out of 194 countries, 50 countries faced 
national-level stockouts at least once a year [2]. Most of the countries facing stockouts were low- to middle-income 
developing countries [2]. These supply interruptions have an impact on global immunization coverage rates [2], which 
can cause the risk of spreading diseases that have been previously controlled.  
All countries are susceptible to supply interruptions and vaccines shortages. In the U.S., over the past decade, there 
was on average one pediatric vaccine interruption per year. The duration of these vaccine shortages varied widely 
from three months to 22 months (see Table A [3]–[9] in the Appendix). Hence, it is reasonable to expect that the 
developing countries with weaker healthcare systems than that in the U.S. may face at least as many vaccine shortages 
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with similar or lengthier duration. Evaluation of the safety stocks to mitigate vaccine shortages requires careful 
consideration, as decision makers in developing countries need to balance costs and their ability to maintain safety 
stocks in limited cold-chain facilities. 
Most of the available literature on safety stock levels of vaccines considers safety stocks composed solely of 
monovalent vaccines, which provide protection against single disease in one shot, whereas combination vaccines 
provide protection against multiple diseases in one shot. Additionally, the vaccine stockpile literature does not 
consider the case when there are multiple suppliers for a vaccine, while in reality UNICEF, the Global Vaccine 
Alliance (GAVI), and WHO try to maintain competition among suppliers to avoid supplier monopolies in the global 
vaccine markets [10], [11]. 
This study aims to determine the stockpile levels for combination vaccines facing uncertain supply interruptions when 
multiple suppliers per vaccine are available in the market. We first develop a simulation model to mimic supply 
shortages under different stockpile configurations and explore the effect of these configurations on the shortage levels 
resulting from different supply interruption scenarios. Second, considering the results of the simulation study, we 
propose a tractable safety stock model. We compare the recommended safety stock levels from the tractable model 
with those resulting from the simulation study. 
The remaining document is divided into four main sections. Section 2 provides a literature review; Section 3 details 
the research question and the hypothesis of this study; and Section 4 describes the methodology, which includes 
simulation study and the formulation of the proposed tractable safety stock model. Section 5 describes the validation 
of the safety stock model, and finally, Section 6 provides concluding remarks and future extensions.  
2. Literature Review 
This section provides an overview of the different approaches used to determine the vaccine stockpile levels used to 
mitigate shortages. Most of the studies reviewed focus on the safety stock levels for monovalent vaccines [8], [12]–
[14], which is inadequate as most countries use combination vaccines in their immunization schedules. However, 
studies that consider combination vaccines [7], [15] fail to consider either the uncertainty in the occurrence of supply 
interruption and assume that the length of the supply interruption is deterministic in nature.  
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In the U.S., the pediatric vaccine stockpile maintains a rotating stock for all its recommended vaccines. By law, the 
country maintains a stock to satisfy six months of the vaccine demand carried out  through the Vaccines for Children 
(VFC) program [15]. The six months of the VFC demand represents only three months of the national demand [16]. 
However, these prescriptive stockpile levels were inadequate to deal with the vaccine supply interruptions observed 
during 2000 and 2012, which lasted up to 22 months [8] (see Appendix Table A for details of shortage events observed 
in the U.S.). 
At the global level, vaccine stockpiles are maintained by international health organizations such as WHO, UNICEF, 
Médecins Sans Frontières (MSF), and the International Federation of the Red Cross (IFRC). WHO currently maintains 
stockpiles for four vaccines—the smallpox, meningococcal, yellow fever, and oral cholera vaccines [17]. UNICEF 
and its partners are currently developing oral polio vaccine (OPV) stockpile [18]. The decision to determine which 
vaccine should be stockpiled for global use and the number of doses to be stored is made by representatives from 
WHO and in some cases in combination with MSF, IFRC, and UNICEF [17],[19]. Decisions on each stockpile level 
are evaluated by discussing different scenarios for each vaccine that considers various factors such as disease 
characteristics, including fatality rates, frequency of observed epidemics, number of countries affected, availability of 
disease detection methods, vaccine efficacy, vaccine availability, and the existence of alternative treatment methods 
[17]. The stockpile levels of the vaccines maintained by WHO and its international partners are shown in Table 2. 
Table 2: Vaccine stockpile doses at international health organizations 
Vaccine Establishment year Doses 
Smallpox vaccine 1980 35 million 
Meningococcal vaccine 1997 9 million 
Yellow fever vaccine 2001 5 million 
Oral cholera vaccine 2013 6 million 
Oral polio vaccine In progress TBD 
Sources: [17], [18], [20], [21] 
In 2006, Jacobson et al. [8] analytically proposed a stochastic safety stock model that minimizes the risk of a vaccine 
supply shortage for monovalent vaccines in the U.S. The model identifies adequate stockpile levels for different 
4 
 
vaccines, considering that supply interruptions and their lengths are random. The supply was assumed to be gradually 
restored via two different ramp-up functions [8]. 
Proaño et al. [13] proposed a multi-attribute utility model to determine the appropriate stockpile level for monovalent 
vaccines considering the need to minimize cost, maximize herd immunity, and minimize the risk of shortages. The 
model determines safety stock levels that optimize utility functions for the vaccine shortages, the coverage rate, and 
the financial cost savings. 
Shrestha et al. [7] introduced ‘VacStockpile,’ a spread-sheet and rule-based tool, to evaluate the impact of stockpile 
levels with six months of supply in the U.S. The tool suggests the number of children that will not receive the 
recommended doses of vaccine for given stockpile levels, considering the likelihood of a finite set of shortage 
scenarios [7]. The model also defines the cost associated with maintaining these stockpile levels considering a finite 
set of monovalent and combination vaccines in stock. However, for combination vaccines, VacStockpile simply 
facilitates the evaluation of all permutations of different likely shortage scenarios and does not pre-emptively provide 
the stockpile levels to be maintained against random supply interruption [16]. 
Truong [22] derived upper and lower bounds for the target stockpile levels for monovalent and combination vaccines. 
The stockpile policy given by Truong [22] is based on a marginal cost analysis approach considering non-linear 
backorder cost with uncertainty in the fulfillment of placed orders. The model is then verified by observing the results 
of 1,000 random instances of these scenarios. The study also shows that there is a significant decrease in stockpile 
level if there is more than one supplier for any particular vaccine [22]. The holding and backorder costs vary widely 
among countries, and it may not always capture the risk of supply interruptions appropriately.  
Thompson and Tebbens [23] proposed a framework for optimal global stockpiles in the form of a stock and flow 
diagram. The framework guides in determining the trade-offs between vaccine stockpile cost and health benefits 
considering the vaccine stockpile to be used during the emergency response to a disease outbreak [23]. The framework 
also highlights the need for improving global vaccine supply efficiency to ensure an adequate vaccines supply and 
provides recommendations for universal vaccines (vaccines having large global demand) and non-universal vaccines 
(new and niche vaccines) [23]. It does not propose a tractable model to determine the optimal stockpile levels and also 
does not consider the existence of multiple vaccines providing similar antigens that can satisfy the demand of antigens. 
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3. Research Question 
In this study we aim to determine what the optimal stockpile level should be for vaccine safety stocks that contain 
combination vaccines to mitigate the risk of uncertain supply interruptions while considering the presence of multiple 
suppliers having different likelihoods of supply interruptions. We also aim to determine the impact on safety stockpile 
levels of choosing to stock vaccines with a high risk of supply interruptions versus using vaccines with a low risk of 
supply interruptions. Without loss of generality, we refer to the first alternative as the policy of stockpiling risky 
vaccines and to the second as the policy of stockpiling robust vaccines. 
To achieve the aforementioned objectives, we apply our proposed methodology to the experimental scenarios designed 
to consider the needs of low-income (LI) and lower-middle-income (LMI) countries served by the WHO African 
region, which has suffered frequent supply interruptions, as observed in the 2015 GVAP secretariat report 
[2],[24],[25]. In particular, we focus on the safety stock of vaccines offering the diphtheria-tetanus-pertussis (DTP), 
haemophilus influenzae type B (Hib) and hepatitis B (HepB) antigens. Such vaccines include monovalent vaccines—
DTwP, Hib, and HepB—and the combination vaccine DTwP-Hib-HepB, usually referred as the pentavalent or penta 
vaccine. 
4. Methodology 
We approach the research problem by first understanding the trends in supply shortage levels of a vaccine as a result 
of changes in the market conditions through a simulation study. We then apply that which was learned from the 
simulation study to develop a prescriptive tractable safety stock model. Section 4.1 explains the simulation study in 
detail, while section 4.2 details the tractable safety stock model.  
4.1 Simulation Study 
We propose a discrete simulation model to mimic different shortage scenarios by considering multiple input factors. 
This simulation model is used within an experimental design to test the effect of the following factors: (1) the number 
of vaccine suppliers, (2) the probability of supply interruption for these suppliers, (3) the length of the supply 
interruption, and (4) the choice of stockpiling policy (i.e., using risky vaccines vs. robust vaccines). In section 4.1, we 
will first describe the overview of the proposed simulation model and then explain in further detail the structure of the 
experimental design along with the set of assumptions considered in our experimentation as well as in the tractable 
model proposed in section 4.2. 
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4.1.1 Simulation Model 
The simulation model mimics the shortage scenarios based on the different inputs and determines the expected 
shortage levels for each of the vaccines constituting the safety stock. The simulation model evaluates shortage levels 
that could happen over a planning horizon of one year for randomly generated instances of supply interruptions. The 
simulation assumes that the impact of a vaccine supply interruption can be mitigated by the use of alternative vaccines 
(some of them being combination vaccines) that provide some or all of the antigens missing due to the vaccine 
shortage. The simulation model consists of two random events: one that determines whether a vaccine will face a 
supply interruption and, if so, the random length of such interruption.  
Figure 1 illustrates the flow of this simulation model. First, the model randomly determines which vaccine supplier 
will undergo a supply interruption based on their probability of having a supply interruption. Then, the model 
randomly determines the length of such interruption based on a given distribution. Then, the shortage level for all the 
antigens provided by the vaccine facing a supply interruption is determined. The resulting deficit of the number of 
antigens serves as a proxy of the expected antigen shortage, which is satisfied by all the vaccines in the safety stock 
that can supply the antigen of the vaccine in shortage. 
The study is conducted using birth cohorts and the immunization schedules of 28 LI and LMI countries in WHO’s 
African region (see Appendix Table B) [24],[25]. The vaccine immunization schedules were obtained from the ‘WHO 
Vaccine-preventable Diseases: Monitoring System, 2016’ [26], and the annual birth cohorts for the countries were 
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As described in Figure 1, the model inputs include the set of vaccines, the set of antigens supplied by those vaccines, 
the set of suppliers of each vaccine, the probability of interruption at each supplier, the distribution of the interruption 
length, and production capacities. The inputs are provided to a model based on the experimental scenario that we want 
to test. Each experimental scenario is replicated 1,000 times. We assume that if there are 𝑛 vaccines supplying antigen 
𝑎 and each vaccine has 𝑚 suppliers, then the total production from these suppliers is equal to the total requirement of 
antigen 𝑎 in the market. Only in cases when there are only combination vaccines in the market and some of the antigens 
contained in the vaccine have a higher number of recommended doses than remaining antigens, it is possible to have 
some surplus for the antigens with lower dose requirements. We assume that both combination vaccines and 
monovalent vaccines are offered in the market, yet a major portion of antigen demand is satisfied via combination 
vaccines. 
For a vaccine 𝑣 supplying a set of antigens 𝑎𝑣, the simulation first determines whether there will be a supply 
interruption at any of its suppliers based on their probability of interruption, which is assumed to be independent from 









• Annual birth 














levels to the 
minimum 
stockpile 


















in the vaccine 
Estimate vaccine 
shortage levels  
Max {𝜑𝑣𝑎. 
Shortage level of 
each antigen}  
For all scenarios 
For every instance 
Figure 1: Simulation model process flow chart 
8 
 
the probabilities of interruption for other suppliers. Then, a second random event takes place that determines the length 
of the supply interruption (in days) for those vaccine suppliers. Interruption length accounts for the time from the 
beginning of the supply interruption until that supplier is back to full production, and during this interval the production 
from the supplier is assumed to be completely halted—that is, no partial production levels are considered in this study. 
It is assumed that the length of an interruption follows a known distribution, whose parameters are provided as inputs 
to the model and can be varied based on the experimental scenario that we test. A truncated normal distribution is 
considered as a preliminary choice to explore the effect of interruption length on shortage levels. A lead time of seven 
days is assumed necessary to account for shipping the vaccines from the supplier to the final destination once the 
random interruption is over.  
After the random interruption length is determined, the model quantifies the shortage levels for each antigen 𝑎𝑣 
resulting from the vaccine in shortage. The shortage level is identified by mapping the unmet antigen needs of the 
population over the period of interruption. The unmet antigen need is determined by comparing the antigen demand 
versus the supply provided by all vaccines containing that antigen during the supply interruption. The antigen demand 
is computed from the daily number of births in the population and number of antigen needed per child to be fully 
immunized. The notation described below and equation (1) provide the mathematical representation of antigen 
demand during the interruption period. 
Let, 
𝐴:   Set of antigens 
𝑉:   Set of vaccines articulated to supply all the antigens 
𝑆:   Set of vaccine suppliers 
𝑆𝑣:  Set of suppliers for vaccine 𝑣 ∈ 𝑉.  𝑆𝑣 ⊂ 𝑆 
𝑉𝑎:  Set of vaccines containing antigen 𝑎 ∈ 𝐴. 𝑉𝑎 ⊂ 𝑉 
𝐴𝑣: Set of antigens supplied by vaccine 𝑣 ∈ 𝑉.   𝐴𝑣 ⊂ 𝐴 
𝐿:  Length of supply interruption in days. 
𝑑𝑎:  Daily demand of antigen 𝑎 ∈ 𝐴 doses. 
𝐶𝑠𝑣:  Daily supply of vaccine 𝑣 ∈ 𝑉 produced by supplier s ∈ 𝑆 
𝑁𝑎:  Need of antigen 𝑎 ∈ 𝐴 during interruption period. 
𝑚𝑣  : Number of suppliers of vaccine 𝑣 ∈ 𝑉. 
𝑝𝑣   :  Probability of interruption for suppliers of vaccine 𝑣 ∈ 𝑉. 
𝑊𝑣𝑎:  Relative importance of vaccine 𝑣 ∈ 𝑉 with respect to supply of antigen 𝑎 ∈ 𝐴. 
9 
 
𝑆𝑢𝑝𝑣 : Total supply of vaccine 𝑣 ∈ 𝑉 per day. 
𝐼𝑣:  Supply shortage level of vaccine 𝑣 ∈ 𝑉. 
 
When there is a supply interruption at supplier 𝑠𝑣 , then supply per day of the vaccine from that supplier 𝐶𝑠𝑣 is stopped 
for the length of the supply interruption. Therefore, the need for antigen 𝑎 across the population during the supply 
interruption of vaccine 𝑣 is given by 
𝑁𝑎 = 𝐿 ∗
(
 𝑑𝑎 − ∑ 𝐶𝑠𝑣
𝑠 ∈ 𝑆𝑣
𝑣 ∈ 𝑉𝑎 )
         ∀ 𝑎 ∈  𝐴   .                     (1) 
The expected shortage level of each vaccine is determined such that the antigen need of each antigen a identified in 
(1) is fulfilled completely by the vaccines 𝑣𝑎 containing antigen a, which may be provided by different suppliers. 
Considering that the proportion of demand for antigen a supplied by vaccine v is expressed as φ𝑣𝑎, then the antigen 
needs 𝑁𝑎 for antigen a when a vaccine is in shortage is fulfilled by all other vaccines supplying that antigen in the 
proportion given by 𝜑𝑣𝑎. Thus, for a vaccine that contains multiple antigens, the expected vaccine shortage level 𝐼𝑣  is 
defined as the maximum of the number of doses required to fulfill the need for the antigen supplied by that vaccine. 
𝐼𝑣 =  𝑚𝑎𝑥(𝑁𝑎 ∗  𝜑𝑣𝑎|𝑎 ∈  𝐴𝑣)           ∀ 𝑣 ∈ 𝑉                     (2) 
The ratio φ𝑣𝑎 is estimated by the relative importance 𝑊𝑣𝑎 of the vaccine v toward the safety stock with respect to the 
overall relative importance of all other vaccines supplying antigen a, as shown in (3). 
𝜑𝑣𝑎 = 
𝑊𝑣𝑎
∑ 𝑊𝑣𝑎𝑣 ∈ 𝑉𝑎
                ∀ 𝑣 ∈ 𝑉 𝑎𝑛𝑑 𝑎 ∈ 𝐴                (3) 
The relative importance of vaccine 𝑣 for the supply of antigen 𝑎 (𝑊𝑣𝑎) is higher as the supply of 𝑣 (𝑆𝑢𝑝𝑣) is high with 
respect to the antigen demand 𝑑𝑎. Also, it is higher as the number of suppliers for 𝑣 (𝑚𝑣) decreases. Whereas As the 
probability of interruption 𝑝𝑣 is high, 𝑊𝑣𝑎 is higher in case of policy to stockpile risky vaccines but it decreases in 
case of policy to stockpile robust vaccines. The expression (4) is used for the policy that stockpiles risky vaccines 
because here 𝑊𝑣𝑎 is directly proportional to the average probability of having a supply interruption. Hence, the relative 
importance of vaccines for the supply of antigen ‘𝑎’ increases as their likelihood of having a supply interruption 
increases. Equation (5) is used for the second policy to stockpile robust vaccines since it considers that 𝑊𝑣𝑎 is directly 
proportional to the probability of not having an interruption at the vaccine supplier. Hence, the relative importance of 
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) ∗ (1 − 𝑝𝑣)         ∀ 𝑣 ∈ 𝑉 𝑎𝑛𝑑 𝑎 ∈ 𝐴            (5) 
 
                                                                                                                   
4.1.2 Experimental Design 
The simulation model described in section 4.1.1 serves as a tool for conducting experiments over scenarios of interest. 
We consider the set of vaccines that contains antigens for DTP that are part of the immunization schedule of the 28 
LI and LMI African countries. According to the 2015 GVAP secretariat report [28], DTP-containing vaccines have 
faced frequent shortages. We assume that the DTP-containing combination vaccine DTwP-Hib-HepB, also called a 
pentavalent vaccine, is available in the market along with the three monovalent vaccines DTwP, Hib, and HepB 
(monovalent vaccines with antigens for DTP, Hib, and HepB, respectively).  
We test two stockpiling policies: policy (A)—stockpiling risky vaccines that are prone to supply interruptions and 
policy (B)—stockpiling robust vaccines that suffer fewer supply interruptions (i.e., that are robust to interruptions). 
When we have both monovalent and combination vaccines in the market, for a given antigen, the shortage level will 
be fulfilled by a safety stock containing both types of vaccines. Based on the experimental combinations, each of these 
vaccine types may have higher or lower probabilities of interruption. So, two different stockpiling policies are tested, 
first in which the larger fraction of the antigen shortage is fulfilled by the stockpile of vaccines with a higher probability 
of interruption and second where stockpiling policy satisfies a larger portion of antigen shortage by stockpiling 
vaccines with a lower probability of interruption. To determine the aforementioned fraction of antigen demand 
satisfied by each type of vaccine, 𝜑𝑣𝑎 from (3) is used. Then, to mimic policy A we use expression (4) for 𝑊𝑣𝑎, while 
expression (5) is used to mimic policy B. We use 2𝑘 factorial design to test the effect of the parameters related to these 
four vaccines on their expected shortage levels.  
We conduct three sets of experiments. Experiment 1 considers that we have both combination and monovalent 
vaccines in the market and that the safety stockpile also contains both combination and monovalent vaccines. Some 
portion of the antigen shortage level is satisfied by combination vaccines, while the remaining portion is satisfied by 
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monovalent vaccines. This portion varies depending upon whether stockpiling policy A or B is used for determining 
stockpile levels. It also depends on the number of vaccine suppliers and their production capacities. In experiment 2, 
we consider that the market has only monovalent vaccines and that these vaccines are the only ones used for the 
stockpile. Hence, for a given antigen during an interruption, its supply is fulfilled by only monovalent vaccines. 
Stockpiling policies A and B do not play any role as we do not have any alternative combination vaccine in the 
stockpile to share the antigen shortage level. For experiment 3, it is considered that the stockpile includes only 
combination vaccines. Even in this experiment stockpiling policies do not play any role as the entire antigen shortage 
during the supply interruption is satisfied by only combination vaccines in the stockpile. Experiments 2 and 3 aim to 
facilitate comparing the expected shortage levels of vaccines when we have only monovalent vaccines in the safety 
stock or only combination vaccines or a mix of combination and monovalent vaccines.  
Certain assumptions are needed to support our analysis. It is assumed that for a given vaccine all its suppliers have the 
same probability of interruption. Also, we assume that for a vaccine, each of its suppliers has equal production 
capacity. For a given antigen, the total supply of all vaccines containing the antigen is enough to satisfy the 
uninterrupted antigen demand and yet there is no excess vaccine supply for a given antigen in the market. However, 
for experiment 3, since there is only pentavalent vaccine in the market to satisfy all antigens’ demand and each antigen 
has different dosage requirements, we allow the over-production of Hib and HepB antigens which require fewer doses 
than the DTP antigen. For experiment 1, when we have both monovalent and combination vaccines together in the 
market, it is assumed that a major portion (60–70%) of the antigen demand in the market is supplied by the 
combination vaccine.  
Next, we describe the actual set up for each of the three experiments. We explain how the four factors that we seek to 
control—that is, the number of vaccine suppliers, the probability of interruption, the mean interruption length, and the 
stockpiling policy—have been incorporated into each of the three experiments. 
4.1.2.1 Experiment 1 
In this experiment, we propose a 210-factorial design resulting from the study of how our four factors of interest affect 
the safety stockpile of each of the four vaccines, DTwP, DTwP-Hib-HepB (penta), Hib, and HepB. The factors 
considered in this experiment are a number of suppliers for each vaccine, the probability of interruption at each 
vaccine’s suppliers, the mean interruption length, and stockpiling policy. Table 3 describes the levels for each factor 
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used in this experiment. The 210-factorial design results in 1,024 experimental scenarios. Each experimental scenario 
is replicated 1,000 times to generate 1,024,000 random instances of supply interruptions. 
Table 3: Factors used in experiment 1 
No. Factors Level 1 Level 2 
Number of suppliers of vaccines 
1 Number of DTwP suppliers 1 7 
2 Number of DTwP-Hib-HepB suppliers 1 7 
3 Number of Hib suppliers 1 7 
4 Number of HepB suppliers 1 7 
Probability of interruption at suppliers 
5 DTwP suppliers’ probability of interruption 0.06 0.2 
6 DTwP-Hib-HepB suppliers’ probability of interruption 0.06 0.2 
7 Hib suppliers’ probability of interruption 0.06 0.2 
8 HepB suppliers’ probability of interruption 0.06 0.2 
Interruption length 
9 Mean interruption length (days) 150 360 
Stockpiling policy 
10 Stockpiling policy A B 
 
The probability of interruption values for each level shown in Table 3 corresponds to the probability of vaccine supply 
interruption over a period of one year. These probabilities are estimated for one year considering that the supply 
interruption happens once in five years (as level 2) or once in 15 years (as level 1). These derived values correspond 
to 0.2 and 0.06 factor levels for the probability of supply interruption, respectively. From 1985 to 2000 (a period of 
15 years), there was no major supply interruption observed in the U.S. [29], while from 2000 onwards to 2012 frequent 
shortage events are observed, as listed in Table A in the Appendix. Thus, the lower factor level for the probability of 
interruption is considered as a supply interruption occurring once in 15 years.  
UNICEF, GAVI, and WHO have worked toward increasing the number of vaccine suppliers in the global market and 
avoiding a monopoly by any single supplier. Due to these efforts, DTP-containing vaccines on an average have six 
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WHO-qualified suppliers in the global market [30]. Hence, a high factor level for the number of suppliers for each 
vaccine is considered to be seven.  
From the 2015 GVAP annual secretariat report [2] and the data shown in Table 1 in the introduction section, it can be 
seen that the average duration of a stockout was at least two months for 2010–2014. These stockouts are reported 
when the safety stock for a three-months’ supply is depleted [2]. Hence, we can assume that a supply interruption can 
last for at least five months. However, from the shortages reported in the U.S. in early 2000 (refer Appendix Table 
A), we see that the supply interruptions lasted for more than a year on average. As we are considering a time horizon 
of one year for the simulation instance, we assume that the maximum interruption over a year can be 12 months (360 
days). 
4.1.2.2 Experiment 2 
In this experimental set, we consider that the safety stock relies exclusively on three monovalent vaccines, DTwP, 
Hib, and HepB. The experimental factors in this experiment are the number of suppliers for each vaccine, the 
probability of interruption at each vaccine’s suppliers, and mean interruption length. The list of factors under 
consideration and the factor levels are given in Table 4. The resulting 27-factorial design is used, which results in 128 
experimental scenarios. Each scenario is also replicated 1,000 times in the simulation model, giving 128,000 instances 
of supply interruption. The assumptions and the selection of the factor levels are justified similarly as that for 
experiment 1. 
Table 4: Factor levels for experiment 2 
No. Factors Level 1 Level 2 
Number of suppliers of vaccines 
1 Number of DTwP suppliers 1 7 
2 Number of Hib suppliers 1 7 
3 Number of HepB suppliers 1 7 
Probability of interruption at suppliers 
4 DTwP suppliers’ probability of interruption 0.06 0.2 





6 HepB suppliers’ probability of interruption 0.06 0.2 
Interruption length 
7 Mean interruption length (days) 150 360 
 
4.1.2.3 Experiment 3 
In this experiment, we consider that only the pentavalent combination vaccine (DTwP-Hib-HepB) is available in the 
market and its safety stock to fulfill any antigen’s demand from a supply interruption of the pentavalent vaccine. Table 
5 shows the factors considered for this experiment and their experimental levels. Here, a 23-factorial design is used, 
resulting in eight experimental scenarios replicated 1,000 times, and thus we have 8,000 instances of supply 
interruption. 
Table 5: Factors used in experiment 3 
No. Factors Level 1 Level 2 
Number of suppliers 
1 Number of DTwP-Hib-HepB suppliers 1 7 
Probability of interruption at suppliers 
2 DTwP-Hib-HepB suppliers’ probability of interruption 0.06 0.2 
Interruption length 
3 Mean interruption length (days) 150 360 
 
4.1.3 Results 
We aim to determine whether there are any significant effects of the key factors on the expected shortage and shortage 
variance for each vaccine under consideration. The expected shortage for a given experimental scenario is computed 
as the mean shortage level across all 1,000 replications of that scenario, and the variance of the shortage for that 
experimental scenario is the variance of the shortage levels across the same 1,000 replications. Also, the analysis is 
performed to determine if there are any differences in expected shortage levels and the costs across experiments 1, 2, 
and 3. 
Experiment 1 includes both combination and monovalent vaccines in the stockpile. We analyze the expected shortage 
of the individual vaccines as well as expected shortages across all vaccines in the safety stock. Figure 2 illustrates the 
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main effects of all factors on the expected shortage across all vaccines. It can be seen that as the number of suppliers 
for each monovalent vaccine increases, the total shortage across all the vaccines decreases. However, as the number 
of suppliers for the penta vaccine increases, there seems to be an increase in the total expected shortage levels. On the 
other hand, if there is an increase in the probability of interruption at any vaccine supplier, the total expected shortage 
level increases. Similar is the effect of interruption length. As the mean interruption length increases, the total expected 
shortage also increases. However, the effect of choice of stockpiling policy on the total expected shortage does not 
seem to be significant. 
Figure 4 shows the main effects plot of the key factors on the expected shortage levels of the individual vaccines. It 
can be seen that when the number of suppliers of the vaccine under consideration increases, there is a decrease in the 
expected shortage level. However, if the number of suppliers of a vaccine containing at least one similar antigen 
increases, there seems to be an increase in the expected shortage level, whereas with the increase in the probability of 
interruption and the mean interruption length, the expected shortage of all the vaccines increases. Also, there is no 
effect of a change in stockpiling policy A or B on any of the vaccine’s expected shortage levels. Additionally, multiple 
two-level interactions of the factors seem to have a significant effect on the expected shortage levels of the vaccine, 
such as number of vaccine suppliers and interruption length, number of vaccine suppliers and probability of 
interruption for the same vaccine suppliers, and number of suppliers of the vaccine under consideration and number 
of suppliers of a vaccine supplying similar antigens to those of the vaccine under consideration. Interaction plots for 




Figure 2: Experiment 1—Main effects of factors on total stockpile levels 
 




Figure 4: Experiment 1—Main effects of factors on individual vaccine expected shortage levels 
 
Figure 5: Experiment 1—Main effects of factors on individual vaccine variance of shortage 
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We also analyzed the variance of individual vaccine shortage and the variance of shortage across all vaccines. Figure 
3 represents the main effects of factors on the variance of total shortage levels. As the number of suppliers of a vaccine 
increases, the total variance of the shortage across all vaccines decreases. Figure 5 shows a variance of an individual 
vaccine shortage. It can be seen that as the number of suppliers of the vaccine under consideration increases, there is 
a decrease in the variance of shortage. However, with an increase in the number of suppliers of vaccines containing at 
least one similar antigen, there seems to be an increase in the variance of a shortage of the vaccine under consideration. 
For all the vaccines, as the probability of interruption and the mean interruption length increase, there is an increase 
in the variance of the vaccine shortage levels. There is no significant effect of stockpiling policy A or B on the variance 
of any vaccine shortage levels. There are, however, significant two-level interaction effects, which are shown in the 
figures A5 and A6 in the Appendix. 
Next, we compare the results from all the three experiments—experiment 1 considering stockpiles of both combination 
and monovalent vaccines, experiment 2 considering of only monovalent vaccines, and experiment 3 considering only 
combination vaccines. We compare the expected shortage levels, the variance of the shortage levels, the expected 
shortage cost, and the variance of the shortage cost for the three experiments. Specifically, we test the following null 
and alternate hypotheses: 
Null Hypothesis: 𝐻𝑜1 =  Mean expected shortage levels are equal for all three experiments 
Alternate Hypothesis: 𝐻𝑎1 = Mean expected shortage level for at least one experiment is not equal 
Null Hypothesis: 𝐻𝑜2 =  Mean variance of the shortage is equal for all three experiments 
Alternate Hypothesis: 𝐻𝑎2 = Mean variance of the shortage for at least one experiment is not equal 
Null Hypothesis: 𝐻𝑜3 =  Mean expected cost of shortage is equal for all three experiments 
Alternate Hypothesis: 𝐻𝑎3 = Mean expected cost of shortage for at least one experiment is not equal 
Null Hypothesis: 𝐻𝑜4 =  Mean variance of shortage cost is equal for all three experiments 
Alternate Hypothesis: 𝐻𝑎4 = Mean variance of shortage cost for at least one experiment is not equal 
We compare the shortage levels from the different experiments because countries have limited space in their cold-
chain facilities, and knowing whether to stock combination and monovalent vaccines or just consider monovalent 
vaccines for safety stock affects the supply chain. Secondly, we also focus on comparing purchasing costs of vaccines 
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for the expected shortage levels because a low cost will increase the affordability of the stockpiles for each country. 
The vaccine prices used in this study are shown in Table 6, which are the weighted average prices (WAP) for the year 
2015 obtained from UNICEF [31],[32]. Generally, it can be seen that monovalent vaccines are less expensive than 
combination vaccines. The Hib vaccine is an exception in our case. Considering these vaccine price conditions, we 
would like to explore the optimal type of vaccine mix that would require the minimum cold-chain space as well as the 
minimum purchasing cost of vaccines in the stockpile. 
Table 6: Weighted average price (WAP) per dose for vaccines under study 
Vaccine DTwP Penta Hib HepB 
Price per dose (USD) 0.28 1.91 4.00 0.18 
Source: [31],[32] 
The box plot of the expected shortage levels, the variance of such shortages, the expected shortage costs, and variance 
of the shortage cost, respectively, for experiments 1, 2, and 3 are shown in Figure 6. We verify the null and alternate 
hypotheses stated above by using a 2-sample t-test. The confidence interval of the difference and the p-values obtained 
from the statistical tests for shortage levels are shown in Table 7, and in Table 8 shortage costs and variance are shown. 
It can be seen here that experiment 3 offers the least expected shortage levels, while experiment 2 results in the highest 
expected shortage levels. Also, the variance of shortage levels is largest for experiment 2, while for experiments 1 and 
3, the variance is similar to each other. Given this, it is preferred not to use only monovalent vaccine stockpiles. When 
we compare the expected costs of shortage, it can be seen that all three experiments have similar expense levels. 
However, the variance of the shortage cost is higher for experiment 2. Thus, for the price per dose of vaccines used in 
this study, which are the actual prices of the four vaccines [31],[32], having only monovalent vaccines results in the 
highest purchasing cost. 
Table 7: Confidence interval (CI) of difference and p-values for expected and variance of shortage levels 
 Expected Shortage Level Variance of Shortage 
 
  Expt 2 Expt 3   Expt 2 Expt 3 
Expt 
1 
CI (Row - Col) 
106 Doses 
(-4.64, -1.49) (1.51, 10.74) 





P-values 0.000 0.016 P-values 0.000 0.798 
Expt 
2 
CI (Row - Col) 
106 Doses NA 
(4.50, 13.88) 
CI (Row - Col) 
1012 Doses2 NA 
(57, 697) 





Figure 6: Box plot showing comparisons of each experiment type 
Table 8: Confidence interval (CI) of difference and p-values for expected shortage cost and its variance 
 Expected Cost of Shortage Variance of Shortage Cost 
   Expt 2 Expt 3   Expt 2 Expt 3 
Expt 
1 
CI (Row - Col) 
106 USD 
(-2.65, 2.95) (-2.38, 15.21) 
CI (Row - Col) 
1012 USD2 
(-25.33, -13.45) (-13.68, 8.87) 
P-values 0.916 0.128 P-values 0.000 0.630 
Expt 
2 
CI (Row - Col) 
106 USD NA 
(-2.78, 15.32) 
CI (Row - Col) 
1012 USD2 NA 
(4.85, 29.13) 
P-values 0.149 P-values 0.010 
 
4.1.4 Simulation Study Summary 
The simulation study shows that if we consider only expected shortage levels for the vaccine stockpiles, we leave a 
substantial amount of risk uncovered since the variance of a shortage is large. Therefore, stockpile levels should be 
determined by taking into account the variance of shortage levels as well. There is a significant effect of the key factors 
on the expected shortage levels and the variances. The expected shortages and the variances decrease when the number 





































































































































Expected Shortage levels Variance of Shortage levels
Expected Cost of Shortage Variance of Shortage Cost
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increase when the probability of interruption and the mean interruption length increase. Stockpiling policies of 
stocking either risky or robust vaccines do not have any significant effect on the expected shortage levels or the 
variance of shortage. Also, it is not recommended to have only monovalent vaccines in the stockpile as it would incur 
a high expected shortage and high shortage variances. For the price conditions considered in this study, the expected 
shortage cost is highest when we have only monovalent vaccines in the stockpile.  
4.2 Tractable Model 
The need to allow those responsible for vaccine inventories across the globe to easily analyze and control their safety 
stock results in the need for tractable safety stock model that can be embedded in spreadsheets and can be easily used 
by policy makers without having to run the simulation. Furthermore, tractable safety stock models facilitate sensitivity 
analysis. Thereby we propose a tractable safety stock model assuming that it could be used as part of a continuous 
review stochastic inventory system such as (𝑅𝑣 ,  𝑄𝑣) for each vaccine 𝑣.  
Without loss of generality consider that 𝑅𝑣 corresponds to the re-order inventory level that triggers an order of size 
𝑄𝑣  to be placed. 𝑆𝑆𝑣 is the safety stock of vaccine 𝑣 𝜖 𝑉. 𝐼𝑙  is the random interruption length for the supply of given 
vaccine 𝑣. 𝑙 is a constant for the delivery time of vaccines from the manufacturer to its destination.  
When the inventory level reaches a re-order point 𝑅𝑣 for a vaccine, a fixed order quantity 𝑄𝑣  is placed during the 
regular supply of vaccines. The inventory satisfies the expected lead-time demand during the time between placing 
the order up to its receipt. In some cases, if the order arrives late due to any given reason, the safety stock can be used 
for mitigating the shortage. However, when the supply interruption of random length 𝐼𝑙  occurs, the vaccines will be 
supplied from the safety stock until the suppliers are back to full production. Thus, the focus of this study is to 
determine the safety stock 𝑆𝑆𝑣 of vaccines, while determining the order quantity 𝑄𝑣 is not in the scope of this study. 
It is assumed that when a supply interruption occurs for a given vaccine, the stockpile is determined for all the vaccines 
supplying antigens similar to the vaccine in shortage such that their stockpiles together satisfy the expected antigen 
shortages. Thus, the 𝑆𝑆𝑣 shown in Figure 6 represents the safety stock of vaccine 𝑣 when a supply interruption for the 












We consider that there are 𝑚𝑣 suppliers for each vaccine with the probability of supply interruption as 𝑝𝑣. It is the 
same for all the suppliers of a given vaccine. For a given vaccine, any number of suppliers 𝑁𝑣 out of the available 𝑚𝑣 
can face a supply interruption. Thus, 𝑁𝑣 can take discrete values ranging from 0 to 𝑚𝑣, where all suppliers for a given 
vaccine have an equal probability of facing supply interruption 𝑝𝑣. Therefore, 𝑁𝑣 is binomially distributed with 
parameters 𝑁𝑣 ~ 𝐵(𝑚𝑣 , 𝑝𝑣). The interruption length 𝐼𝑙  is also considered as a random variable with known distribution 
parameters. Additionally, the safety stock must offer a service level of 𝛼 so that the probability that a stockout will 
not happen during the supply interruption lead-time is 𝛼%. The interruption lead-time consists of a constant time 𝑙 to 
distribute vaccines to the destination in addition to the random interruption length 𝐼𝑙 . 
4.2.1 Formulation of Safety Stock Model 
Let us consider following notations for the sets, the parameters, and the variables. 
Sets: 
𝐴:  Set of antigens 
𝑉:  Set of vaccines 
𝐴𝑣:  Set of antigens supplied by vaccine 𝑣 𝜖 𝑉, 𝐴𝑣 ⊂ 𝐴 
𝑉𝑎:  Set of vaccines supplying antigen 𝑎 𝜖 𝐴, 𝑉𝑎 ⊂ 𝑉 
Parameters: 
Consumption rate 






Figure 7: Continuous review stochastic inventory model for vaccine stockpiles 
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𝑆𝑢𝑝𝑣:  Total supply of vaccine 𝑣 𝜖 𝑉 per day across all suppliers 
𝑚𝑣: Number of suppliers of vaccine 𝑣 𝜖 𝑉 
𝑝𝑣: Probability of supply interruption at suppliers of vaccine 𝑣 𝜖 𝑉 
𝜑𝑣𝑎: Fraction of antigen 𝑎 𝜖 𝐴 demand supplied by vaccine 𝑣 𝜖 𝑉  
𝑙 : Constant for the delivery time of vaccines from manufacturer to destination once supply is restored 
Variables: 
𝐼𝑙  : 𝑟. 𝑣 Interruption length following a known distribution with mean 𝜇𝐼𝑙 and standard deviation 𝜎𝐼𝑙  
𝑁𝑣: 𝑟. 𝑣 Number of suppliers of vaccine 𝑣 𝜖 𝑉 out of 𝑚𝑣 facing supply interruption over a year. Given that 
probability of interruption at vaccine supplier is 𝑝𝑣 , hence, 𝑁𝑣~𝐵(𝑚𝑣, 𝑝𝑣) 
𝐸[𝑁𝑣]:  𝑚𝑣𝑝𝑣 
𝑉[𝑁𝑣]:  𝑚𝑣𝑝𝑣(1 − 𝑝𝑣) 
𝐾𝑣: 𝑟. 𝑣 Supply shortage levels of vaccine 𝑣 𝜖 𝑉 when vaccine 𝑣 faces supply interruption 
𝐷𝑎: 𝑟. 𝑣 Lead-time demand for antigen 𝑎 𝜖 𝐴 across all vaccines facing interruption 
𝐷𝑣: 𝑟. 𝑣 Lead-time demand for vaccine 𝑣 𝜖 𝑉 due to any common antigen supplying vaccines facing interruption 
In the first step, we determine 𝐾𝑣 the supply shortage of vaccine 𝑣 that is itself facing a supply interruption of length 
(𝑙 + 𝐼𝑙). 𝐾𝑣 is a product of total supply of vaccine 𝑣 per day per supplier, the number of suppliers facing supply 




. 𝑁𝑣 .  (𝑙 + 𝐼𝑙)                        (6) 
As 𝑁𝑣 and 𝐼𝑙  are random variables, the expected supply shortage and its variance for a vaccine 𝑣 facing supply 
interruption correspond to (7) and (8), respectively [33],[34]. 
𝐸[𝐾𝑣] =  𝐸 [
𝑆𝑢𝑝𝑣
𝑚𝑣
𝑁𝑣(𝑙 +  𝐼𝑙)] 
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. 𝐸[𝑁𝑣].  (𝑙 + 𝐸[𝐼𝑙])   .          (7) 
Variance of 𝐾𝑣 is given by 
𝑉[𝐾𝑣] =  𝑉 [
𝑆𝑢𝑝𝑣
𝑚𝑣
𝑁𝑣(𝑙 +  𝐼𝑙)] 
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Expanding the terms 
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2)), 
since 𝑉[𝑙 +  𝐼𝑙] = V[𝐼𝑙] 𝑎𝑛𝑑 𝐸[𝑙 +  𝐼𝑙] = 𝑙 + 𝐸 [𝐼𝑙], then 





. (𝑉[𝑁𝑣]. 𝑉[𝐼𝑙] + 𝑉[𝑁𝑣]. 𝐸[𝑙 +  𝐼𝑙]
2 +  𝐸[𝑁𝑣]
2. 𝑉[𝐼𝑙])           (8) 
 
In the second step, we determine the expected antigen lead-time demand and its variance as a consequence of the 
vaccine supply shortages. Thus, the expected lead-time demand of each antigen corresponds to the sum of the supply 
shortages across all the vaccines containing the given antigen. Similarly, the variance of the antigen lead-time demand 
is the sum of the variances of all the vaccines supplying the given antigen. 
𝐸[𝐷𝑎] =  ∑ 𝐸[𝐾𝑣]
𝑣 𝜖 𝑉𝑎
             ∀ 𝑎 ∈ 𝐴          (9) 
𝑉[𝐷𝑎] =  ∑ 𝑉[𝐾𝑣]
𝑣 𝜖 𝑉𝑎
            ∀ 𝑎 ∈ 𝐴          (10) 
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Finally, in the third step, we determine the expected lead-time demand and its variance for vaccines containing 
antigens similar to those of the vaccines facing supply interruption. Thus, the vaccine expected lead-time demand and 
its variance are a function of the antigen lead-time demand and variance. 
Since more than one vaccine supplies a given antigen, we estimate 𝜑𝑣𝑎, the fraction of antigen 𝑎 ∈ 𝐴 demand supplied 
by vaccine 𝑣 ∈ 𝑉, which is shown in (3). 
When a vaccine 𝑣 supplies multiple antigens, we determine the fraction of expected antigen demand to be supplied 
by the given vaccine for each antigen contained in that vaccine. Let 𝑎 be the antigen for which the vaccine 𝑣 needs to 
supply the highest expected number of doses. It is represented by the following expression: 
𝑎 = Arg
𝑎1
(max{𝜑𝑣𝑎1 . 𝐸[𝐷𝑎1] | 𝑎1 𝜖 𝐴𝑣}) . 
Then the expected vaccine lead-time demand 𝐸[𝐷𝑣] and its variance 𝑉[𝐷𝑣] must account for largest antigen shortage, 
𝐸[𝐷𝑣] = 𝜑𝑣𝑎 . 𝐸[𝐷𝑎]              (11) 
𝑉[𝐷𝑣] = 𝜑𝑣𝑎
2 .  𝑉[𝐷𝑎]             (12) 
Now, we determine the safety stock that ensures a desired service level 𝛼. By its definition the probability of having 
no stockouts during interruption lead-time is equal to 𝛼%, 
𝑃(𝐷𝑣 ≤  𝑅𝑣) =  𝛼 = Probability of no stockout during leadtime    ,        (13)  
where inventory re-order level corresponds to 
𝑅𝑣 = 𝐸[𝐷𝑣] +  𝑆𝑆𝑣     where 𝑆𝑆𝑣 = Safety Stock of vaccine       .          (14) 
Subtracting 𝐸[𝐷𝑣] from both sides of inequality in (13) and dividing by 𝜎𝐷𝑣  obtained from (12) we obtain 
𝑃 (





) =  𝛼. 
By the central limit theorem and the definition of a standardized normal variable, 
𝑃 (𝑍 ≤  
𝑆𝑆𝑣
𝜎𝐷𝑣
) ≤  𝛼 
𝑆𝑆𝑣 =  𝑍𝛼√𝑉[𝐷𝑣] 
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Substituting 𝑉[𝐷𝑣] from (12) 
𝑆𝑆𝑣 =  𝑍𝛼√𝜑𝑣𝑎
2 .  𝑉[𝐷𝑎]                   (15) 
(15) corresponds to the safety stock that will ensure 𝛼% service level during the interruption. Similarly, we can define 
the re-order level at which orders must be placed when the system does not face supply interruption, 
𝑅𝑣 = 𝜑𝑣𝑎. 𝐸[𝐷𝑎] +  𝑍𝛼√𝜑𝑣𝑎
2 .  𝑉[𝐷𝑎] 
 
5. Model Validation 
To validate the tractable safety stock model as shown in (15), we will compare its results with the simulation results 
for the same experimental scenarios performed in the simulation study. To perform this comparison, we will use 
distributions and input parameters similar to those we used for the simulated experimental scenario.  
We follow a truncated normal distribution for the interruption length, as used in the simulation study. From the mean 
and standard deviation of normal distribution denoted by 𝑁(𝜇𝐼𝑙, 𝜎𝐼𝑙) we determine the mean and standard deviation of 
truncated normal distribution 𝑁𝑇(𝜇𝑡𝐼𝑙  , 𝜎𝑡𝐼𝑙) by using following equations: 











2 =  𝜎𝐼𝑙






















 ) , 
where  
𝜙( ) : Probability Density Function (p. d. f) of normal distribution 
 𝛷( ): Cumulative Density Function (c. d. f) of normal distribution 
Thus, if we substitute the mean and variance of 𝐼𝑙  following truncated normal distribution and 𝑁𝑣 following binomial 
distribution, the expressions (7) and (8) for 𝐸[𝐾𝑣] and 𝑉[𝐾𝑣] are given by 
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𝐸[𝐾𝑣] =  
𝑆𝑢𝑝𝑣
𝑚𝑣
.  𝑚𝑣𝑝𝑣 . (𝑙 +  𝜇𝑡𝐼𝑙) 





{𝑚𝑣𝑝𝑣(1 − 𝑝𝑣).  𝜎𝑡𝐼𝑙




2 } . 
Then, the expected antigen lead-time demand and variance remain the same as (9) and (10) 
𝐸[𝐷𝑎] =  ∑ 𝐸[𝐾𝑣]
𝑣 𝜖 𝑉𝑎
 
𝑉[𝐷𝑎] =  ∑ 𝑉[𝐾𝑣]
𝑣 𝜖 𝑉𝑎
 . 
The expected vaccine lead-time demand and variance are as given by (11) and (12) 
𝐸[𝐷𝑣] = 𝜑𝑣𝑎 . 𝐸[𝐷𝑎] 
𝑉[𝐷𝑣] = 𝜑𝑣𝑎




(max{𝜑𝑣𝑎1 . 𝐸[𝐷𝑎1] | 𝑎1 𝜖 𝐴𝑣}) . 
We use the above expressions and obtain the stockpile level for the shortage scenarios described in experiment 1 (refer 
to section 4.1.2.1) without considering stockpiling policy as one of the experimental factors since it has no effect on 
the vaccine shortage level, as seen in the simulation study. Now, from the simulation study, we obtain the expected 
vaccine shortages and their variance for each experimental scenario of experiment 1. The expected vaccine shortage 
from the simulation can also be termed as the expected vaccine lead-time demand during the interruption, and thus 
the computed shortage variance can be used in expression (15) to obtain the safety stock of vaccines for those 
simulated experimental scenarios. Thus, we have the expected vaccine lead-time demand and stockpile levels from 
two different approaches, and we compare them using a 2-sample t-test. Table 9 summarizes the results of the 2-
sample t-test for each vaccine. The null and alternate hypotheses that we want to test are as follows: 
𝐻05: Mean of [𝐸[𝐷𝑣]]𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 = Mean of [𝐸[𝐷𝑣]]𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑚𝑜𝑑𝑒𝑙  
𝐻𝑎5: Mean of [𝐸[𝐷𝑣]]𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛  ≠  Mean of [𝐸[𝐷𝑣]]𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑚𝑜𝑑𝑒𝑙  
𝐻06: Mean of [𝐸[𝑆𝑆𝑣]]𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 = Mean of [𝐸[𝑆𝑆𝑣]]𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑚𝑜𝑑𝑒𝑙  
𝐻𝑎6: Mean of [𝐸[𝑆𝑆𝑣]]𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 ≠  Mean of [𝐸[𝑆𝑆𝑣]]𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑚𝑜𝑑𝑒𝑙  
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Table 9: Summary of 2-sample t-test comparison of expected lead-time demand and safety stock of vaccines 
Vaccine 















DTwP 3.6 3.67 0.07 (-0.44, 0.30) 0.710 6.64 6.96 -0.322 (-0.99, 0.35) 0.345 
Penta 4.74 5.97 -1.229 (-1.65, -0.81) 0.000 8.43 9.46 -1.021 (-1.78, -0.27) 0.008 
Hib 1.92 1.95 -0.032 (-0.26, 0.19) 0.780 3.39 3.56 -0.168 (-0.51, 0.18) 0.338 
HepB 1.92 1.95 -0.028 (-0.25, 0.19) 0.803 3.39 3.58 -0.19 (-0.54, 0.15) 0.279 
 
From the statistical comparison shown in Table 9, we can see that the expected lead-time demand and the safety stock 
levels of all the three vaccines, DTwP, Hib, and HepB, match very well with the simulation results. However, the 
penta vaccine’s expected lead-time demand and the safety stock from the tractable model seem underestimated. We 
plotted a scatterplot of the safety stock levels from the simulation on X-axis and the tractable model on the Y-axis 
with a line of equality at a 45-degree angle (refer to Figure 8) for the same experimental scenarios. It can be seen that 
the stockpile levels from the tractable model and the simulation study are aligned along the line of equality for all 
three vaccines. However, for the penta vaccine, the stockpile levels deviate away from the line of equality, showing 
the differences in the tractable model and the simulation results. The underestimation of the stockpile levels from the 
tractable model is observed only for combination vaccines, which means an evaluation of the vaccine’s expected lead-
time demand and its variance (refer to (11) and (12)) when the vaccine is supplying more than one antigen, provides 
lower values than the simulation results. The deviation from the equality line is smaller when the stockpile levels are 




Figure 8: Scatterplot with line of equality—comparing stockpile levels from simulation study and tractable model 
Applying the tractable safety stock model to the same scenarios used in experiments 1, 2, and 3 from our simulation 
study, we compare the stockpile levels for different types of vaccine mixes (refer to sections 4.1.2.1, 4.1.2.2, and 
4.1.2.3). We evaluate the safety stock levels for having both combination and monovalent vaccines together in the 
safety stock, only monovalent vaccines, and only combination vaccines, respectively. Figures 9 shows the boxplot of 
the stockpile levels and the cost of purchasing such stockpiles for each type of the vaccine mix. Boxplot of stockpile 
levels illustrates that having only monovalent vaccines results in the highest stockpile levels as compared with the 
other two vaccine mixes. Therefore, it is preferable not to have stockpiles that constitute only monovalent vaccines 
since it puts excessive pressure on the cold-chain needs. Additionally, with the price of vaccines used in this study, 
the purchasing cost is highest for the monovalent vaccine stockpiles. Thus, monovalent vaccine stockpiles are also not 
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Figure 9: Stockpile levels and stockpile cost comparison for different vaccine mixes 
The purchasing costs of vaccines in stockpiles with only combination vaccines and with a mix of combination and 
monovalent vaccines are statistically the same. The results of the 2-sample t-test in Table 10 shows that the differences 
in stockpile levels and cost are statistically insignificant for stockpiles with only combination vaccines and stockpiles 
with a mix of combination and monovalent vaccines.  
Table 10: 2-sample t-test results for stockpile levels and stockpile cost 
  






18.68 21.86 -3.17 (-12.92, 6.58) 0.468 
Stockpile Cost 
(M USD) 
35.69 32.14 3.55 (-15.06, 22.17) 0.665 
 
To evaluate the price conditions under which having only monovalent vaccines in the stockpile would be a preferred 
option, we performed a cost analysis by varying the price of the monovalent vaccine Hib as USD 0.64 per dose instead 
of USD 4.00. The graphical analysis of the stockpile cost with the new price for the Hib vaccine is shown in Figure 
10. The stockpile cost of monovalent vaccines became as attractive as those of the other two safety stock 
configurations. However, as we observed in Figure 9, the stockpile quantity for monovalent vaccines is rather high. 
The stockpile levels with only combination vaccines and with a mix of combination and monovalent vaccine are 
similar, but under the revised price conditions of monovalent vaccines, the cost of a stockpile with a mix of 
combination and monovalent vaccines is much lower than that of a stockpile with only combination vaccines. 
Therefore, it is preferred to have a stockpile of a mix of combination and monovalent vaccines to facilitate lower 




Figure 10: Revised stockpile cost for each type of vaccine mix with Hib price as USD 0.64 
6. Conclusion 
The tractable safety stock model developed in this study can be used to determine the stockpile levels for any of the 
combination or monovalent vaccines with multiple suppliers, varying likelihoods of supply interruption, and random 
interruption lengths.  
Three out of the four key factors considered in the study affect the safety stock levels significantly. The stockpile level 
decreases with an increase in the number of suppliers of the vaccine. However, it increases when the probability of 
interruption at the suppliers or the mean interruption length increases. The stockpile levels are not affected when we 
switch from the policy to stockpile risky vaccines to the policy to stockpile robust vaccines. 
The analysis of stockpile quantity and the stockpile purchasing cost for different types of vaccine mixes shows that it 
is preferred to have stockpiles with a mix of combination and monovalent vaccines since this results in lower stockpile 
levels as compared to having only monovalent vaccine stockpiles and lower purchasing costs as compared to having 
only combination vaccine stockpiles.  
The tractable inventory model allows one to perform a sensitivity analysis with ease. Thus, this study can be extended 
to perform a sensitivity analysis to understand the range of the input parameters for which the stockpile levels would 
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Table A: List of examples for pediatric vaccine shortages in US 




Tetanus and Diphtheria 
toxoids/Tetanus Toxoid (Td/TT) 
November, 
2000 
19 Change in manufacturing process, 
manufacturer leaving market 
Diphtheria and Tetanus toxoids 




Change in manufacturing process, 
manufacturer leaving market 










Change in manufacturing process 
Pneumococcal Conjugate 
Vaccine (PCV)  
August, 2001 
22 























Hepatitis A July, 2007 9  




19 Manufacturer recalled lots of vaccines both 
monovalent and combination doses 
Diptheria and Tetanus toxoids and 
acellular Pertusis vaccine (DTaP) 
April, 2012 
18 Manufacturer cannot meet demand 
requirements 




Table B: [24], [25]Low Income and Lower Middle Income countries of WHO Africa region 
Sr No Countries 
1 Benin 
2 Burkina Faso 
3 Burundi 
4 Cabo Verde 
5 Cameroon 
6 Chad 

















22 Sierra Leone 










Figure A1: Percentage of countries by WHO region facing stockout (2010-2014) 
 
Figure A2: Percentage of countries by Income group facing the vaccine shortages 
 
32





















2014 2013 2012 2011 2010
Percentage of Countries by Region
AMR AFR EMR EUR SEAR WPR



















2014 2013 2012 2011 2010
Percentage of Countries by Income Group




Figure A3: Experiment 1- Interaction effects of factors on total expected shortage levels 
 




Figure A5: Experiment 1- Interaction effects of factors on total shortage variance 
 
Figure A6: Experiment 1- Interaction effects of factors on individual vaccine shortage variance 
